Seroatlas · Human Serome Atlas

TPRA1

Transmembrane protein adipocyte-associated 1

Also known as: FLJ32197, GPR175, TMEM227, TPRA1_HUMAN, TPRA40

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86W33
Gene: TPRA1
Ensembl: ENSG00000163870
Chromosome: 3
Canonical length: 373 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Vesicles

OverviewNCBI Gene

Predicted to enable G protein-coupled receptor activity. Predicted to be involved in G protein-coupled receptor signaling pathway. Predicted to act upstream of or within embryonic cleavage and negative regulation of mitotic cell cycle phase transition. Predicted to be located in membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

373 residues, UniProt reviewed canonical sequence.

>Q86W33|TPRA1
     1  MDTLEEVTWA NGSTALPPPL APNISVPHRC LLLLYEDIGT SRVRYWDLLL LIPNVLFLIF
    61  LLWKLPSARA KIRITSSPIF ITFYILVFVV ALVGIARAVV SMTVSTSNAA TVADKILWEI
   121  TRFFLLAIEL SVIILGLAFG HLESKSSIKR VLAITTVLSL AYSVTQGTLE ILYPDAHLSA
   181  EDFNIYGHGG RQFWLVSSCF FFLVYSLVVI LPKTPLKERI SLPSRRSFYV YAGILALLNL
   241  LQGLGSVLLC FDIIEGLCCV DATTFLYFSF FAPLIYVAFL RGFFGSEPKI LFSYKCQVDE
   301  TEEPDVHLPQ PYAVARREGL EAAGAAGASA ASYSSTQFDS AGGVAYLDDI ASMPCHTGSI
   361  NSTDSERWKA INA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TPRA1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0.4
Highest tissue expression: 35 nTPM

Expression across tissuesHPA

Tissue

skin: 35 nTPM
liver: 33 nTPM
choroid plexus: 30 nTPM
cervix: 29 nTPM
parathyroid gland: 27 nTPM
adrenal gland: 25 nTPM

Single-cell type

endometrial secretory cells: 163 nCPM
neutrophils: 148 nCPM
cdc: 124 nCPM
esophageal apical cells: 121 nCPM
monocytes: 91 nCPM
syncytiotrophoblasts: 83 nCPM

Immune cell

classical monocyte: 13 nTPM
myeloid DC: 13 nTPM
eosinophil: 12 nTPM
plasmacytoid DC: 9.7 nTPM
intermediate monocyte: 9.5 nTPM
memory CD8 T-cell: 9.5 nTPM

Brain region

choroid plexus: 29 nTPM
cerebral cortex: 28 nTPM
thalamus: 25 nTPM
hypothalamus: 25 nTPM
midbrain: 24 nTPM
cerebellum: 23 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.71
gnomAD pLI: 0.01
gnomAD missense Z: 0.52
DepMap mean gene effect: -0.13
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

G protein-coupled receptor activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

Transmembrane protein TPRA1/CAND2/CAND8
Predicted membrane protein

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TPRA1 as an antibody target. Whether an autoantibody or antibody against TPRA1 could matter depends on whether native TPRA1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TPRA1 is annotated at the cell surface, where native TPRA1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TPRA1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...